US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)

Trial Profile

US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2014

At a glance

  • Drugs Tamoxifen (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CAPTURE
  • Sponsors Midatech Pharma US
  • Most Recent Events

    • 13 Mar 2014 Status changed from recruiting to active, no longer recruiting based on information reported in a DATA BioSciences media release.
    • 13 Mar 2014 Results will be presented at the National Comprehensive Cancer Network (NCCN) 19th Annual Conference: Advancing the Standard of Cancer Care according to a DARA BioSciences media release. Results were also reported in the media release.
    • 14 Aug 2013 DARA BioSciences has enrolled 13 US oncology centres and completed nearly 50% of the patient surveys in this registry, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top